NDC 0074-2100

Skyrizi

Risankizumab-rzaa

Skyrizi is a Subcutaneous Injection in the Human Prescription Drug category. It is labeled and distributed by Abbvie Inc.. The primary component is Risankizumab.

• Product ID: 0074-2100_05c4dbfd-4d63-4c5f-950b-cca935a753c3
• NDC: 0074-2100
• Product Type: Human Prescription Drug
• Proprietary Name: Skyrizi
• Generic Name: Risankizumab-rzaa
• Dosage Form: Injection
• Route of Administration: SUBCUTANEOUS
• Marketing Start Date: 2021-04-26
• Marketing Category: BLA /
• Application Number: BLA761105
• Labeler Name: AbbVie Inc.
• Substance Name: RISANKIZUMAB
• Active Ingredient Strength: 150 mg/mL
• Pharm Classes: Interleukin-23 Antagonist [EPC], Interleukin-23 Antagonists [MoA]
• NDC Exclude Flag: N
• Listing Certified Through: 2023-12-31

Packaging

NDC 0074-2100-01

1 SYRINGE in 1 CARTON (0074-2100-01) > 1 mL in 1 SYRINGE

• Marketing Start Date: 2021-04-26
• NDC Exclude Flag: N
• Sample Package?: N

Drug Details

NDC Crossover Matching brand name "Skyrizi" or generic name "Risankizumab-rzaa"

NDC	Brand Name	Generic Name
0074-1050	Skyrizi	risankizumab-rzaa
0074-1065	Skyrizi	Risankizumab-rzaa
0074-1070	Skyrizi	Risankizumab-rzaa
0074-2042	Skyrizi	Risankizumab-rzaa
0074-2100	Skyrizi	risankizumab-rzaa